Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310107674> ?p ?o ?g. }
- W4310107674 endingPage "2305" @default.
- W4310107674 startingPage "2302" @default.
- W4310107674 abstract "Background : Outcome of relapse/refractory (R/R) peripheral T-cell lymphoma (PTCL) patients (pts) is usually poor. [Mak, 2013]. Brentuximab vedotin (Bv) monotherapy is approved for R/R anaplastic large cell-lymphoma (ALCL) with long term responders [Pro, 2017] and for 1st line in association with polychemotherapy [Horwitz, 2019] in all CD30+ PTCL (with no restriction related to expression cut-off). We designed a phase 2 study for R/R CD30+ PTCL combining gemcitabine (G) and Bv with the aim to increase the overall response rate (ORR) by 15%, compared to gemcitabine monotherapy (35%) [O'Connor, 2019] and among secondary endpoints to evaluate BV maintenance and the impact of both CD30 expression and soluble CD30 (sCD30) on response and survival. Patients and Methods: : Patients with confirmed CD30+ (≥5%) PTCL with measurable disease who failed or were refractory to 1-3 systemic therapy (excluding G and Bv) and ECOG performance status < 3 were eligible. Pts received 4 (28-days) cycles of G and Bv induction phase (GBvIP) (G : 1000mg/m² at D1 and D15 plus Bv: 1.8 mg/kg at D8) followed, in pts with complete (CR) or partial remission (PR) and non-eligible for SCT, by up to 12 (21-days) cycles of Bv (1.8 mg/kg) maintenance phase (BvMP). The primary endpoint was ORR (CR + PR) according to Lugano criteria (CT-scan-based). CD30 expression was semi-quantitatively assessed by immunohistochemistry (IHC) and serum sCD30 levels were determined by ELISA. (NCT03496779). Results: From April 2018 to October 2019, 71 pts with PTCL (47 males, 24 females) were enrolled. Central pathology review according to 2017 WHO criteria found nodal TFH-PTCL (34 ; 47.9%) [including AITL (27 ; 38%) and other nodal PTCL-TFH (7 ; 9.9%)] ; ALK- ALCL (14 ; 27%) ; PTCL-NOS (9 ; 13%) ; ALK+ ALCL (5 ; 7%), EATL (2 ; 2.8%) and other entities (7 ; 9.9%). Median age was 66 years (20-79), 65 pts (91.6%) were stage III-IV. ECOG status was ≥ 2 in 45 pts (63%). The number of prior lines were 1 (57), 2 (11) or 3 (3) and 28 pts (39.4%) had a refractory disease. In intention to treat analysis, the ORR after GBvIP was 46.5% including CR (14;19.7%), PR (19;26.8%). Among the 33 responders, 27 initiated BvMP as well as 1 non responding pt (with SD but a complete metabolic response). The median number of BvMP cycles was 9 (range 1-12). At least one G≥3 AE were recorded in 58/71 pts during GBvIP and 11/28 pts during BvMP. AE led to treatment discontinuation in 9/71 pts (GBvIP) and 14/28 pts (BvMP). Overall a polyneuropathy of G≥1 was recorded in 9/71 pts (GBvIP) and 14/28 pts (BvMP). After a median follow-up of 26.5 (0.5-42.1) months (mo), the median progression free survival (PFS) and overall survival (OS) were respectively 4.5 mo (95%CI [3.5 - 10]) (Figure 1A) and 12.9 mo (95%CI [8.6 - 25.5]). Among the 33 pts in PR/CR after GBvIP, the duration of response since inclusion (DOR) was 15.8 mo (95%CI [10.4 - (-)]) By univariate analysis, ORR was negatively influenced by high LDH (p=0.008) with borderline impact of ECOG (p=0.058), and both PFS and OS were reduced by refractory disease status at screening (p=0.031 and p=0.007) and non-ALCL histology (p=0.049 and p=0.041). CD30 expression was investigated on tumor samples collected either at screening (55.5%) or (if not available) at diagnosis (39,7%) or at previous relapse (4.8%). In pts with ALCL, CD30 expression was constant and high (>75% of tumor cells) along with a significant higher level of sCD30 compared to non ALCL pts. In non ALCL pts, the median % of CD30-positive tumor cells was 12.5% [0 - 12.5]. Focusing on non-ALCL pts we found a high impact of sCD30 level >120 ng/mL on both ORR, DOR, PFS and OS while CD30 expression on tumor cells did not appear to influence the results. (Figure 1B ; Table 1) Conclusion : According to our initial hypothesis, the addition of Bv to G is active in R/R CD30+ PTCLs both in terms of ORR, CR. In responding pts, the DOR exceeding 15 mo with very long responders suggests the value of Bv maintenance. Not surprisingly ALCL were associated with better results, but this treatment is also effective in non ALCL pts including a significant proportion of TFH lymphoma pts. Besides ALCL pts, biomarkers are needed to predict which pts could benefit the most of Bv based therapy. In line with a previous report [Horwitz, 2014], we did not find a clear impact of CD30 expression on tumor cells, however we demonstrate that baseline serum sCD30 at treatment initiation was strongly correlated with both response and outcome. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
- W4310107674 created "2022-11-30" @default.
- W4310107674 creator A5005690652 @default.
- W4310107674 creator A5007139107 @default.
- W4310107674 creator A5009196800 @default.
- W4310107674 creator A5010558253 @default.
- W4310107674 creator A5011860927 @default.
- W4310107674 creator A5012725632 @default.
- W4310107674 creator A5012900514 @default.
- W4310107674 creator A5013488023 @default.
- W4310107674 creator A5013649293 @default.
- W4310107674 creator A5013996935 @default.
- W4310107674 creator A5014942120 @default.
- W4310107674 creator A5015230787 @default.
- W4310107674 creator A5016122215 @default.
- W4310107674 creator A5021807846 @default.
- W4310107674 creator A5025168447 @default.
- W4310107674 creator A5029209393 @default.
- W4310107674 creator A5031977714 @default.
- W4310107674 creator A5033073385 @default.
- W4310107674 creator A5043543553 @default.
- W4310107674 creator A5045374333 @default.
- W4310107674 creator A5047928065 @default.
- W4310107674 creator A5049919069 @default.
- W4310107674 creator A5051605599 @default.
- W4310107674 creator A5052071966 @default.
- W4310107674 creator A5053019069 @default.
- W4310107674 creator A5055854759 @default.
- W4310107674 creator A5059687021 @default.
- W4310107674 creator A5062422990 @default.
- W4310107674 creator A5063891068 @default.
- W4310107674 creator A5065987951 @default.
- W4310107674 creator A5068452218 @default.
- W4310107674 creator A5070246382 @default.
- W4310107674 creator A5073135494 @default.
- W4310107674 creator A5074135845 @default.
- W4310107674 creator A5077504536 @default.
- W4310107674 creator A5079890028 @default.
- W4310107674 creator A5079928258 @default.
- W4310107674 creator A5082232325 @default.
- W4310107674 creator A5084278083 @default.
- W4310107674 creator A5085150178 @default.
- W4310107674 creator A5089493611 @default.
- W4310107674 date "2022-11-15" @default.
- W4310107674 modified "2023-10-16" @default.
- W4310107674 title "Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. the TOTAL Trial" @default.
- W4310107674 doi "https://doi.org/10.1182/blood-2022-165217" @default.
- W4310107674 hasPublicationYear "2022" @default.
- W4310107674 type Work @default.
- W4310107674 citedByCount "0" @default.
- W4310107674 crossrefType "journal-article" @default.
- W4310107674 hasAuthorship W4310107674A5005690652 @default.
- W4310107674 hasAuthorship W4310107674A5007139107 @default.
- W4310107674 hasAuthorship W4310107674A5009196800 @default.
- W4310107674 hasAuthorship W4310107674A5010558253 @default.
- W4310107674 hasAuthorship W4310107674A5011860927 @default.
- W4310107674 hasAuthorship W4310107674A5012725632 @default.
- W4310107674 hasAuthorship W4310107674A5012900514 @default.
- W4310107674 hasAuthorship W4310107674A5013488023 @default.
- W4310107674 hasAuthorship W4310107674A5013649293 @default.
- W4310107674 hasAuthorship W4310107674A5013996935 @default.
- W4310107674 hasAuthorship W4310107674A5014942120 @default.
- W4310107674 hasAuthorship W4310107674A5015230787 @default.
- W4310107674 hasAuthorship W4310107674A5016122215 @default.
- W4310107674 hasAuthorship W4310107674A5021807846 @default.
- W4310107674 hasAuthorship W4310107674A5025168447 @default.
- W4310107674 hasAuthorship W4310107674A5029209393 @default.
- W4310107674 hasAuthorship W4310107674A5031977714 @default.
- W4310107674 hasAuthorship W4310107674A5033073385 @default.
- W4310107674 hasAuthorship W4310107674A5043543553 @default.
- W4310107674 hasAuthorship W4310107674A5045374333 @default.
- W4310107674 hasAuthorship W4310107674A5047928065 @default.
- W4310107674 hasAuthorship W4310107674A5049919069 @default.
- W4310107674 hasAuthorship W4310107674A5051605599 @default.
- W4310107674 hasAuthorship W4310107674A5052071966 @default.
- W4310107674 hasAuthorship W4310107674A5053019069 @default.
- W4310107674 hasAuthorship W4310107674A5055854759 @default.
- W4310107674 hasAuthorship W4310107674A5059687021 @default.
- W4310107674 hasAuthorship W4310107674A5062422990 @default.
- W4310107674 hasAuthorship W4310107674A5063891068 @default.
- W4310107674 hasAuthorship W4310107674A5065987951 @default.
- W4310107674 hasAuthorship W4310107674A5068452218 @default.
- W4310107674 hasAuthorship W4310107674A5070246382 @default.
- W4310107674 hasAuthorship W4310107674A5073135494 @default.
- W4310107674 hasAuthorship W4310107674A5074135845 @default.
- W4310107674 hasAuthorship W4310107674A5077504536 @default.
- W4310107674 hasAuthorship W4310107674A5079890028 @default.
- W4310107674 hasAuthorship W4310107674A5079928258 @default.
- W4310107674 hasAuthorship W4310107674A5082232325 @default.
- W4310107674 hasAuthorship W4310107674A5084278083 @default.
- W4310107674 hasAuthorship W4310107674A5085150178 @default.
- W4310107674 hasAuthorship W4310107674A5089493611 @default.
- W4310107674 hasBestOaLocation W43101076741 @default.
- W4310107674 hasConcept C126322002 @default.
- W4310107674 hasConcept C142424586 @default.
- W4310107674 hasConcept C143998085 @default.
- W4310107674 hasConcept C159985019 @default.
- W4310107674 hasConcept C192562407 @default.